
NextPoint Therapeutics' Vice President, Biology Matt Rausch will attend #SITC2026, Nov. 4–8. Our lead program, NPX372, is in Phase 1 development, with early data showing signs of T cell activation. Attending SITC? Connect with Matt to discuss our B7-H7 programs.
















